AU2001292119A1 - Absorption enhancers - Google Patents

Absorption enhancers

Info

Publication number
AU2001292119A1
AU2001292119A1 AU2001292119A AU9211901A AU2001292119A1 AU 2001292119 A1 AU2001292119 A1 AU 2001292119A1 AU 2001292119 A AU2001292119 A AU 2001292119A AU 9211901 A AU9211901 A AU 9211901A AU 2001292119 A1 AU2001292119 A1 AU 2001292119A1
Authority
AU
Australia
Prior art keywords
absorption enhancers
hydrophilic aromatic
gut
uptake
lumen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292119A
Inventor
Roger Randal Charles New
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcess Ltd
Original Assignee
PROXIMA CONCEPTS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROXIMA CONCEPTS Ltd filed Critical PROXIMA CONCEPTS Ltd
Publication of AU2001292119A1 publication Critical patent/AU2001292119A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the use of hydrophilic aromatic alcohols to enhance the uptake of molecules, including biologically active macromolecules, into the body across the intestinal wall from the lumen of the gut; to compositions for oral administration which consists of an enteric capsule capable of withstanding transit through the stomach, containing a mixture comprising: (a) an active principal, and (b) a hydrophilic aromatic alcohol absorption enhancer; and to the user of the composition in medical treatment and diagnosis.
AU2001292119A 2000-10-06 2001-10-05 Absorption enhancers Abandoned AU2001292119A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0024543 2000-10-06
GB0024543A GB2368792A (en) 2000-10-06 2000-10-06 Absorption enhancers
PCT/GB2001/004464 WO2002028436A1 (en) 2000-10-06 2001-10-05 Absorption enhancers

Publications (1)

Publication Number Publication Date
AU2001292119A1 true AU2001292119A1 (en) 2002-04-15

Family

ID=9900822

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292119A Abandoned AU2001292119A1 (en) 2000-10-06 2001-10-05 Absorption enhancers

Country Status (10)

Country Link
US (1) US7303762B2 (en)
EP (1) EP1326644B1 (en)
AT (1) ATE332147T1 (en)
AU (1) AU2001292119A1 (en)
DE (1) DE60121355T2 (en)
DK (1) DK1326644T3 (en)
ES (1) ES2267818T3 (en)
GB (1) GB2368792A (en)
PT (1) PT1326644E (en)
WO (1) WO2002028436A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405169C (en) * 2000-04-03 2011-07-26 Battelle Memorial Institute Devices and formulations
JP2004526674A (en) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート Method for stabilization of biomolecules in liquid formulations
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0603252D0 (en) 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
BRPI0711119A2 (en) 2006-05-02 2011-08-30 Actogenix Nv microbial administration of obesity-associated intestinal peptides
US8236360B2 (en) * 2007-05-02 2012-08-07 Tom's Of Maine, Inc. Supercritical CO2 liquorice extract and products made there from
US8877266B2 (en) 2007-05-02 2014-11-04 Tom's Of Maine, Inc. Supercritical CO2 liquorice extract anti-microbial and anti-inflammatory isolates and products made there from
US20080274063A1 (en) * 2007-05-02 2008-11-06 Chantal Bergeron Supercritical CO2 liquorice extract anti-microbial and anti-inflammatory isolates and products made there from
CA2755068C (en) 2009-03-12 2018-11-06 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
EP3095484B1 (en) 2011-11-02 2018-05-02 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
AU2012332265B2 (en) 2011-11-02 2016-11-10 Keybioscience Ag Peptide analogs for treating diseases and disorders
CN104507309B (en) 2012-03-19 2017-05-03 奇达拉治疗公司 Dosing regimens for echinocandin class compounds
KR101748053B1 (en) 2012-10-17 2017-06-15 메틸레이션 사이언시즈 인터내셔널 에스알엘 Compositions comprising s-adenosylmethionine and a gallic acid ester
WO2014179325A1 (en) * 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Omega-3 fatty acid formulations for use as pharmaceutical treatment
EP3321278B1 (en) 2013-11-14 2019-01-09 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61267528A (en) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd Transnasal calcitonin agent containing absorbefacient
US4804541A (en) * 1987-08-11 1989-02-14 Moleculon, Inc. Transdermal administration using benzyl alcohol
AT391269B (en) 1988-12-30 1990-09-10 Burghart Kurt PHARMACEUTICAL PREPARATION
IT1251685B (en) * 1991-10-11 1995-05-19 Isf Spa PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN
WO2000074736A1 (en) * 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same

Also Published As

Publication number Publication date
US20040028736A1 (en) 2004-02-12
ATE332147T1 (en) 2006-07-15
WO2002028436A1 (en) 2002-04-11
DE60121355D1 (en) 2006-08-17
DE60121355T2 (en) 2007-06-28
EP1326644A1 (en) 2003-07-16
DK1326644T3 (en) 2006-11-06
GB2368792A (en) 2002-05-15
GB0024543D0 (en) 2000-11-22
US7303762B2 (en) 2007-12-04
ES2267818T3 (en) 2007-03-16
EP1326644B1 (en) 2006-07-05
PT1326644E (en) 2006-11-30

Similar Documents

Publication Publication Date Title
AU2001292119A1 (en) Absorption enhancers
ES2519540T3 (en) Compressed pharmaceutical compositions comprising PEG and electrolytes
RS20090105A (en) Medicament compositions based on tiotropium salts and on salmetrol salts
NZ544645A (en) Use of calcitonin in osteoarthritis
DE50203456D1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
IE57989B1 (en) Ddavp antidiuretic and method therefor
HUP0105481A2 (en) Pharmaceutical compositions containing clarithromycin and process for their preparation and their use
HUP0203303A2 (en) Compositions for administering taxanes orally to human patients
HK1079421A1 (en) Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US20190070080A1 (en) Artificial Saliva
SI1326592T1 (en) Use of polyethylene glycol ( peg ) for the manufacture of a medicament for the treatment of constipation
EA200801305A1 (en) APPLICATION OF CYCLETHANIN AND OTHER FUROPYRIDINES FOR THE TREATMENT OF HYPERTENSION WITH THE PREVENTION OF SYTOLIC PRESSURE, ISOLATED SYSTOLIC HYPERTENSION, ENHANCED PULSE ARTERYAL ARMERIAL HYPERTENSION, HYPROPEDIUM ARTHERIC HYPERTENSIA
WO2010092436A1 (en) Pharmaceutical combinations of simethicone and otilonium
NO20024673D0 (en) Controlled-release pharmaceutical composition for oral use containing midodrine and / or desglymidodrine
TW200517119A (en) Method of treatment using interferon-tau
GB0114672D0 (en) Pharmaceutical formulations and methods of medical treatment
MD2323G2 (en) Use of S-ethyl isothiouronium bromide (isoturon) as uterotonic preparation for treatment of uterine hemorrhages in case of uterine myoma
IL117564A (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
BR0016469A (en) Composition to improve the proliferative response during adaptation of the gastrointestinal tract and use in small intestine syndrome
RU2180532C2 (en) Method for treating the cases of papillomatosis
EP1758922B8 (en) Peptide substance restoring function of respiratory organs
RU2238742C2 (en) Method for treating and preventing relapses of uncomplicated forms of gastric and duodenal ulcerous disease
Wegman, EA,* Berman, A.* & Pokorny How to investigate the patient with halitosis
RU98101627A (en) MAGAKYAN ETERNAL SYRUP
RU2001122151A (en) DRUG FOR TREATMENT OF ACUTE POST-NENAL ENDOMETRITIS IN COWS AND METHOD OF ITS APPLICATION